Idorsia
Idorsia UK represents the British operations of the Swiss biopharmaceutical company developing innovative medicines for unmet medical needs in sleep medicine, cardiovascular disease, and rare diseases. The company’s portfolio includes QUVIVIQ (daridorexant), a dual orexin receptor antagonist for the treatment of chronic insomnia in adults.


How to Contact Idorsia
Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.




